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Abstract: While studying respiratory infections of unknown etiology we detected Saffold 
virus in an oropharyngeal swab collected from a two-year-old female suffering from diarrhea 
and respiratory illness. The full viral genome recovered by deep sequencing showed 98% 
identity to a previously described Saffold strain isolated in Japan. Phylogenetic analysis 
confirmed the Peruvian Saffold strain belongs to genotype 3 and is most closely related to 
strains that have circulated in Asia. This is the first documented case report of Saffold virus 
in Peru and the only complete genomic characterization of a Saffold-3 isolate from the Americas. 
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1. Introduction 
Saffold virus (SAFV) was first described in 2007, after it was isolated from a stool sample taken in 
San Diego, in 1981, from an eight-month-old female with fever of unknown origin [1]. SAFV belongs 
to the Cardiovirus genus of the Picornaviridae family. The Cardiovirus genus is composed of two 
species, encephalomyocarditis virus, for which only one serotype has been reported, and Theilovirus, 
for which 14 distinct serotypes are known: SAFV 1–11, Theiler’s murine encephalomyelitis virus, Thera 
virus, and Vilyuisk human encephalomyelitis virus [2]. SAFVs are ubiquitous in populations around the 
world and have been linked to respiratory and gastrointestinal infections early in life [3–6]. Despite their 
extensive distribution, only a handful of SAFV genomic sequences from the Americas have been 
described [7–9]. Furthermore, many of the sequences publicly available are not complete genomes, but 
rather very small fragments of partial VP1 sequences. Aside from its original 1981 isolation in the USA, 
SAFV-1 has only been reported in Bolivia [9]. Other serotypes, including SAFV-2, 4, and 9, have been 
reported in Bolivia, Brazil, Canada, and the USA [7–9]. For the remaining serotypes, including  
SAFV-3, 5, 6, 7, 8, 10, and 11, there are no known reports of isolates from the Americas. Here, we 
provide complete genomic characterization of a SAFV-3 isolate collected from a two-year-old female 
from the Amazonian area of Maynas, in Loreto, Peru. 
2. Results and Discussion 
The SAFV strain described here was isolated from an oropharyngeal swab collected from a  
two-year-old female who presented with diarrhea, heart murmur, and symptoms of respiratory illness, 
including headache, sore throat, cough, rhinorrea, and dyspnea. The patient was identified during routine 
respiratory surveillance efforts carried out by investigators from the U.S. Naval Medical Research Unit 
No.6 in Peru and neighboring countries, with institutional review board approval from all implicated 
partners (Protocols NMRCD.2010.0010 and NMRCD.2010.0008). The sample was initially cultured in 
LLC-MK2, MDCK, and Vero-E6 cells, but by day 18 cytopathic effect (CPE) had only been observed 
in LLC-MK2 cells and no pathogens had been identified in the original sample using traditional PCR or 
ELISA-based approaches. Additional analyses of the CPE-positive LLC-MK2 culture supernatant, using 
a highly multiplexed MassTag PCR approach that can detect over 20 respiratory pathogens 
simultaneously (Influenza viruses A and B; respiratory syncytial viruses A and B; human parainfluenza 
viruses 1–4; human metapneumovirus; coronavirus OC43 and 229E; enterovirus; rhinovirus; 
adenovirus; Chlamydia pneumoniae; Legionella pneumophila; Mycoplasma pneumoniae; Streptococcus 
pneumoniae; Neisseria meningitidis; Haemophilus influenzae; Mycobacterium tuberculosis; Moraxella 
catarrhalis; and Bordetella pertussis) [10], also failed to identify any potential etiology. The sample then 
entered a pathogen discovery pipeline based on unbiased next-generation sequencing that eventually 
produced a match to a Japanese isolate of SAFV-3 (Accession #HQ902242.1) with 98% identity at the nt 
level. The consensus sequence generated (Figure 1) has been named SAFV-3-Maynas-Loreto-Peru-2012 
(Accession #KP972594) based on the location and year of sample collection. The contig is 8064 nt in 
length and contains a complete open reading frame (ORF) of 2296 aa. 
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Figure 1. Schematic representation of the genomic organization of the SAFV polyprotein, 
including all genes (L, VP1, VP2, VP3, VP4, 2A, 2B, 2C, 3A, 3B, 3C, and 3D) drawn to 
approximate scale (top), followed by the corresponding coverage depth by Illumina 
sequencing (bottom). 
To further characterize our strain, we conducted phylogenetic analyses of both the full genome (ORF 
only, 6888 nt, 2296 aa) and the complete viral protein 1 (VP1) (810 nt, 270 aa). This latter region is 
expected to be under positive selection in order to avoid recognition by the host’s immune system, and 
thus could potentially return different phylogenetic results when compared to the whole genome. To 
maintain sampling diversity as large as possible, trees were constructed using publicly available 
reference sequences that represent the totality of the diversity of SAFV strains in terms of genotype, year 
of isolation, and geographical origin (Table 1). The full genome tree includes 34 complete genome 
sequences covering serotypes 1–11, whereas the full VP1 tree includes the same 34 sequences used for 
the full genome tree plus 7 additional available sequences containing complete VP1 genes. Phylogenetic 
analyses of both full genome and complete VP1 sequences confirm that the Peruvian SAFV strain 
collected in 2012 belongs to genotype 3 and is most closely related to Asian strains (Figure 2). We also 
constructed an additional VP1 tree, this time containing partial VP1 sequences available from several 
Bolivian isolates (Figure S1). Although there are minor differences in the branching patterns of the two 
VP1 trees, the Peruvian strain remains closely associated with Asian strains within the SAFV-3 group 
despite the fact that a number of additional South American SAFV strains were included in the analysis. 
The fact that the Peruvian isolate is most closely related to SAFV strains that have circulated in Asia 
rather than in Europe, for example, should not be surprising given the available information. Specifically, 
there are no other reports of SAFV-3 from any country in the Americas, indicating that information from 
additional American strains will be needed to establish more robust phylogenetic relationships in support 
of theories of SAFV movements throughout the world. As it stands, the information presented here can 
only be used to support grouping of the Peruvian SAFV strain into group 3, with particular similarity to 
Asian strains. Nevertheless, it is worth noting that Peru has historically received a large number of 
immigrants from Asia, particularly from China and Japan. Along with further characterization of 
additional strains, this observation could be used to support a theory of introduction of SAFV into the 
Americas directly from Asia. 
Pathogens 2015, 4 819 
 
 
 
Figure 2. Cont. 
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Figure 2. Phylogenetic analyses of SAFV full genome (A) and complete VP1 (B) sequences. 
Each strain is labeled using standard identifiers, including virus type, country of isolation 
(using ISO country codes), isolate name (if any), year of isolation, and GenBank accession 
number. Additionally, SAFV1-11 serotypes are color-coded for easy viewing. The Peruvian 
isolate described here is highlighted in bold and with an arrow. Full genome trees were 
constructed using a total of 36 publicly available complete genome sequences covering 
serotypes 1–11. Full VP1 trees were constructed using those same sequences plus 17 
additional sequences containing complete VP1 genes. Scale bars represent the number of 
substitutions per site. 
3. Experimental Section 
3.1. Cell Culture 
Oropharyngeal swabs were inoculated into Rhesus monkey kidney (LLC-MK2), Madin-Darby canine 
kidney (MDCK), and African Green monkey kidney (Vero-E6) cells grown in E-MEM (Quality 
Biological, 112-018-101. Quality Biological Inc.: Gaithersburg, MD, USA) supplemented with 10% 
fetal bovine serum (Sigma, F4135. Sigma-Aldrich Co.: St. Louis, MO, USA), 1× sodium pyruvate 
(Quality Biological, 116-079-721), 1× antibiotic/antimycotic solution (Sigma, A5955), and 100U/mL 
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penicillin-streptomycin (Gibco, 15140-122. Thermo Fisher Scientific: Waltham, MA, USA). Cultures 
were maintained at 37 °C and 5% CO2 until was observed. 
3.2. MassTag PCR 
CPE-positive culture supernatants were extracted using the QIAamp cador pathogen mini kit 
(QIAGEN, 54104. QIAGEN: Valencia, CA, USA) according to the manufacturer’s instructions and 
nucleic acids were analyzed by MassTag PCR essentially as described [10,11]. Briefly, RNAs were 
reverse-transcribed using SuperScript II (Thermo Fisher, 18064-014) and random primers (Thermo 
Fisher, 48190-011). Reverse transcription products were amplified using a panel of primers labeled with 
photocleavable mass codes (Agilent, custom. Agilent Technologies: Santa Clara, CA, USA) targeting 
Influenza viruses A and B, respiratory syncytial viruses A and B, human parainfluenza viruses 1–4, 
human metapneumovirus; coronavirus OC43 and 229E, enterovirus, rhinovirus, and adenovirus. Upon 
removal of unincorporated primers, tags were released by UV irradiation and analyzed using a 6100 
Series Single Quadrupole LC/MS System (Agilent Technologies). 
3.3. Sequencing Library Preparation 
CPE-positive culture supernatants were preserved in TRIzol LS (Thermo Fisher, 10296-028)  
and RNA was extracted using Direct-zol™ RNA MiniPrep kit (Zymo Research, R2050) according  
to the manufacturer’s instructions. RNAs were converted to cDNA and amplified using  
sequence-independent single primer amplification as described [12] with the following modifications. 
To enhance coverage of the terminal ends, an oligo containing three rGTP at the 3′ end 
(GCCGGAGCTCTGCAGATATCGGCCATTATGGCCrGrGrG) and the FR40RV-T primer [12] were 
added during first-strand synthesis and the reverse transcriptase was changed to Maxima H Minus 
(Thermo Fisher, EP0751), which has terminal transferase activity that enables addition of the rGTP 
containing oligo to the 5′ end during cDNA synthesis. Amplicons were sheared to ~400 bp and used as 
starting material for TRUseq libraries (Illumina FC-121-4001. Illumina, Inc.: Hayward, CA, USA) 
prepared according to the manufacturer’s instructions. 
3.4. Sequencing and Bioinformatics 
Sequencing was performed on a MiSeq using a 300 cycle kit (Illumina MS-102-2002). Cutadapt [13] 
and Prinseq-lite [14] were used to trim primers and remove poor quality reads, respectively. Reads were 
assembled into contigs using Ray Meta [15] and annotation was done by BLAST in combination with 
custom scripts. 
3.5. Phylogenetics 
A number of available SAFV sequences were downloaded from GenBank to serve as references 
(Table 1). To cover as many genotypes, years, and geographical regions as possible, we considered 34 
complete genomes (at least 6888 nt covering all 2296 aa of representative SAFV1-11 isolates, including 
the Peruvian isolate), 17 complete VP1 sequences (810 nt covering all 270 aa), and seven additional 
partial VP1 sequences (at least 312 nt) specifically from the Americas. Theiler’s murine encephalomyelitis 
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virus and Theilers-like virus genomes were used as outgroups in the analysis. Alignments were 
constructed using Muscle and trees were generated using the Maximum Likelihood algorithm with 2000 
bootstrap replicates in Mega 6.0 [16,17]. Genetic distances were calculated using a General Time 
Reversible Gamma Distributed model. 
Table 1. Sequences used for phylogenetic analysis. The Peruvian isolate is highlighted in 
gray. Sequences from isolates with complete genomes were used for both full genome and 
VP1 phylogenetic trees. Sequences from isolates with partial VP1 sequences were used for 
an additional VP1 tree that is almost identical to the complete VP1 tree (Figure S1). 
Abbreviations: SAFV-Saffold virus; TMEV-Theiler’s murine encephalomyelitis virus. 
Virus Accession # Year Location Sequence Type Length (nt) 
SAFV-1 NC_009448.2 1981 USA Complete genome 8115 
SAFV-1 JX219488.1 2002 Bolivia Partial VP1 321 
SAFV-1 JX219490.1 2003 Bolivia Partial VP1 356 
SAFV-1 JX122403.1 2007 China Complete genome 7856 
SAFV-1 GU126466.1 2008 China Complete VP1 822 
SAFV-1 AB747177.1 2009 Afghanistan Complete VP1 847 
SAFV-1 AB747248.1 2009 Pakistan Complete genome 8078 
SAFV-2 JX219484.1 2002 Bolivia Partial VP1 357 
SAFV-2 JX219485.1 2003 Bolivia Partial VP1 376 
SAFV-2 EU681176.2 2004 Germany Complete genome 7842 
SAFV-2 JN652231.1 2005 USA Complete genome 7885 
SAFV-2 EU376394.1 2005–2006 USA Complete genome 7961 
SAFV-2 EU681177.2 2006 Brazil Complete genome 7809 
SAFV-2 AM922293 2006 Canada Complete genome 6882 
SAFV-2 FR682076.2 2008 Finland Complete genome 8046 
SAFV-2 FN999911.1 2008 Netherlands Complete genome 8045 
SAFV-2 FJ463601.1 2008 Pakistan Complete VP1 816 
SAFV-2 AB747182.1 2009 Afghanistan Complete VP1 856 
SAFV-2 GU943518.1 2009 China Complete genome 7846 
SAFV-2 AB747249.1 2009 Pakistan Complete genome 8075 
SAFV-2 JX163901.1 2011 Australia Complete genome 7781 
SAFV-3 HM181996.1 1998 Netherlands Complete genome 7984 
SAFV-3 EU681179.2 2004 Germany Complete genome 7846 
SAFV-3 HM181998.1 2004 Netherlands Complete genome 7991 
SAFV-3 HM181999.1 2005 Netherlands Complete genome 7991 
SAFV-3 GU126465.1 2007 China Complete VP1 810 
SAFV-3 AB542806.1 2007 Japan Complete VP1 813 
SAFV-3 FM207487.1 2007 Netherlands Complete genome 8051 
SAFV-3 FJ463605.1 2007 Pakistan Complete VP1 810 
SAFV-3 GU943513.1 2008 China Complete genome 8054 
SAFV-3 HQ902242.1 2008 Japan Complete genome 8082 
SAFV-3 AB747185.1 2009 Afghanistan Complete VP1 835 
SAFV-3 GU943514.1 2009 China Complete genome 7853 
SAFV-3 HQ162476.1 2009 Malaysia Complete genome 8073 
SAFV-3 AB747250.1 2009 Pakistan Complete genome 8079 
SAFV-3 JQ820265.1 2011 Australia Complete VP1 843 
SAFV-3 KP972594 2012 Peru Complete genome 8064 
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Table 1.Cont. 
Virus Accession # Year Location Sequence Type Length (nt) 
SAFV-4 JX219486.1 2002 Bolivia Partial VP1 315 
SAFV-4 JX219487.1 2003 Bolivia Partial VP1 312 
SAFV-4 FJ463606.1 2006 Pakistan Complete VP1 813 
SAFV-4 FJ463600.1 2008 Pakistan Complete VP1 813 
SAFV-4 AB747184.1 2009 Afghanistan Complete VP1 845 
SAFV-4 AB747251.1 2009 Pakistan Complete genome 8027 
SAFV-5 FJ463616.1 2007 Pakistan Complete genome 7639 
SAFV-5 AB747252.1 2009 Pakistan Complete genome 8083 
SAFV-6 FJ463617.1 2007 Pakistan Complete genome 7410 
SAFV-6 AB747181.1 2009 Afghanistan Complete VP1 822 
SAFV-6 AB747253.1 2009 Pakistan Complete genome 8084 
SAFV-7 FJ463602.1 2007 Afghanistan Complete VP1 816 
SAFV-7 AB747254.1 2009 Pakistan Complete genome 8087 
SAFV-8 FJ463604.1 2008 Pakistan Complete VP1 810 
SAFV-8 AB747255.1 2009 Pakistan Complete genome 8081 
SAFV-9 JX219494.1 2002 Bolivia Partial VP1 343 
SAFV-9 FJ997532.1 2007 Nigeria Complete VP1 789 
SAFV-9 AB747256.1 2009 Pakistan Complete genome 8081 
SAFV-10 AB747257.1 2009 Pakistan Complete genome 8083 
SAFV-11 AB747183.1 2009 Afghanistan Complete VP1 829 
SAFV-11 AB747258.1 2009 Pakistan Complete genome 8079 
TMEV X56019.1 1990 USA Complete genome 8101 
Theilers-like virus AB090161.1 2002 Japan Complete genome 8021 
4. Conclusions 
Our case report constitutes the first isolation of SAFV in Peru and the only complete genomic 
characterization of a SAFV-3 isolate from the Americas. Although the characteristics of the patient from 
whom the specimen was isolated agree with previous reports that the virus affects young children and 
that it is linked to both respiratory and gastrointestinal infections, little is known about the prevalence of 
SAFV infections in South American populations. At least two serological studies in Peru have shown the 
presence of neutralizing antibodies to closely related viruses of the Cardiovirusgenus [18,19]. One of these 
studies reported that 21% of the population of the Amazonian city of Iquitos had neutralizing antibodies 
to encephalomyocarditis virus [18]. Interestingly, the authors also reported elevated cross-reactivity rates 
(43.5%), suggesting that many sero-conversions could be due to the presence of closely related members 
of the Cardiovirus genus, including SAFV. Upcoming studies looking specifically at SAFVs should help 
elucidate both the prevalence and virulence of these pathogens, particularly in vulnerable populations. In 
turn, these may allow more robust characterizations of SAFV evolution in the Americas. 
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